Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients
- 28 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (3), 416-426
- https://doi.org/10.1093/cid/ciaa652
Abstract
Invasive fungal infections (IFIs) are common following lung transplantation. Isavuconazole is unstudied as prophylaxis in organ transplant recipients. We compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung transplant recipients. A single-center, retrospective study of patients who received isavuconazole (September 2015–February 2018) or voriconazole (September 2013–September 2015) for antifungal prophylaxis. IFIs were defined by EORTC/MSG criteria. Patients received isavuconazole (n = 144) or voriconazole (n = 156) for median 3.4 and 3.1 months, respectively. Adjunctive inhaled amphotericin B (iAmB) was administered to 100% and 41% of patients in the respective groups. At 1 year, 8% of patients receiving isavuconazole or voriconazole developed IFIs. For both groups, 70% and 30% of IFIs were caused by molds and yeasts, respectively, and breakthrough IFI (bIFI) rate was 3%. Outcomes did not significantly differ for patients receiving or not receiving iAmB. Independent risk factors for bIFI and breakthrough invasive mold infection (bIMI) were mold-positive respiratory culture and red blood cell transfusion >7 units at transplant. Bronchial necrosis >2 cm from anastomosis and basiliximab induction were also independent risk factors for bIMI. Isavuconazole and voriconazole were discontinued prematurely due to adverse events in 11% and 36% of patients, respectively (P = .0001). Most common causes of voriconazole and isavuconazole discontinuation were hepatotoxicity and lack of oral intake, respectively. Patients receiving ≥90 days prophylaxis had fewer IFIs at 1 year (3% vs 9%, P = .02). IFIs were associated with increased mortality (P = .0001) and longer hospitalizations (P = .0005). Isavuconazole was effective and well tolerated as antifungal prophylaxis following lung transplantation.Funding Information
- National Institutes of Health (R21AI126157, R21AI142049, R21AI144390, R21AI128338, K08AI114883, R03AI144636)
This publication has 39 references indexed in Scilit:
- Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and ToxicityAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Voriconazole in AdultsAntimicrobial Agents and Chemotherapy, 2012
- Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)Clinical Infectious Diseases, 2010
- Epidemiology and outcome of invasive fungal infections in solid organ transplant recipientsTransplant Infectious Disease, 2010
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaThe New England Journal of Medicine, 2007
- Prophylaxis and Aspergillosis — Has the Principle Been Proven?The New England Journal of Medicine, 2007
- AspergillusInfections in Transplant RecipientsClinical Microbiology Reviews, 2005
- Pulmonary Aspergillosis in Cystic Fibrosis Lung Transplant RecipientsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1998
- Pulmonary Aspergillosis Following Post-influenzal Bronchopneumonia Treated with AntibioticsBMJ, 1952